Mereo BioPharma Group plc (MREO)
Automate Your Wheel Strategy on MREO
With Tiblio's Option Bot, you can configure your own wheel strategy including MREO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MREO
- Rev/Share 0.0
- Book/Share 0.0766
- PB 4.4122
- Debt/Equity 0.0124
- CurrentRatio 8.9234
- ROIC -0.7904
- MktCap 268710000.0
- FreeCF/Share -0.0423
- PFCF -8.0959
- PE -5.6175
- Debt/Assets 0.0109
- DivYield 0
- ROE -0.6934
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
---|---|---|---|---|---|---|---|
Initiation | MREO | JP Morgan | -- | Overweight | -- | $7 | March 27, 2025 |
Initiation | MREO | Jefferies | -- | Buy | -- | $7 | Dec. 6, 2024 |
News
Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI
Published: July 10, 2025 by: Seeking Alpha
Sentiment: Positive
Mereo BioPharma Group plc's phase 3 ORBIT study for setrusumab in osteogenesis imperfecta will continue to final analysis, expected by end of 2025. The recent 35% MREO stock drop was due to not meeting early efficacy stopping criteria of ORBIT, not due to safety or trial failure. The ongoing phase 2/3 ORBIT study is targeting OI patients ages 5 to 25, while the phase 3 COSMIC trial is going after patients ages 2 to < 7 years.
Read More
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Negative
Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.
Read More
MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock?
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Positive
MEREO BIOPHARMA (MREO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
About Mereo BioPharma Group plc (MREO)
- IPO Date 2019-04-24
- Website https://www.mereobiopharma.com
- Industry Biotechnology
- CEO Denise Vera Scots-Knight
- Employees 36